Eicosapentaenoic acid (EPA)
metaboliteEPA is an anti-inflammatory omega-3 polyunsaturated fatty acid that reduces systemic inflammation, triglycerides and overall atherosclerotic cardiovascular risk.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleOmega-3 fatty acid with anti-inflammatory and triglyceride-lowering effects; systemic risk modifier, not a direct cascade mechanistic marker.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresIndeterminate
R — rupture / Type-I—
C — non-Type-I48
A — assay feasibility42
E — evidence strength48
T1DI (composite)7
Specificity differential (R−C)-32.6
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 1
2high-demand / peri-operative stressmag 1
3sudden cardiac deathmag 1
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedmag 1
Coverage: 7/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 13 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(3)
- Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.Clinical chemistry · 2021 · PMID 33257928 · doi
- The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease.Postgraduate medicine · 2019 · PMID 31063407 · doi
- Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.Atherosclerosis · 2015 · PMID 26253795 · doi
Clinical trials(1)
- Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 DiabetesNCT06129526 · PHASE4 · UNKNOWN · EPAVasc, Corn Oil